Literature DB >> 21677297

Quality achievement and disease prevalence in primary care predicts regional variation in renal replacement therapy (RRT) incidence: an ecological study.

Neil Dhoul1, Simon de Lusignan, Olga Dmitrieva, Paul Stevens, Donal O'Donoghue.   

Abstract

BACKGROUND: Diabetes Meillitus (DM) and hypertension (HT) are important causes of end-stage renal disease (ESRD) and renal replacement therapy (RRT) is the standard active treatment. Financially, incentivized quality initiatives for primary care include pay-for-performance (P4P) in DM and HT. Our aim was to examine any effect of disease prevalence and P4P on RRT incidence and regional variation.
METHODS: The incidence of RRT, sex and ethnicity data and P4P disease register and achievement data were obtained for each NHS locality. We calculated correlation coefficients for P4P indicators since 2004/05 and socio-demographic data for these 152 localities. We then developed a regression model and regression coefficient (R(2)) to assess to what extent these variables might predict RRT incidence.
RESULTS: Many of the P4P indicators were weakly but highly significantly correlated with RRT incidence. The strongest correlation was 2004/05 for DM prevalence and 2006/07 for HT quality. DM prevalence and the percentage with blood pressure control in HT target (HT quality) were the most predictive in our regression model R(2) = 0.096 and R(2) = 0.085, respectively (P < 0.001). Combined they predicted a fifth of RRT incidence (R(2) = 0.2, P < 0.001) while ethnicity and deprivation a quarter (R(2) = 0.25, P < 0.001). Our final model contained proportion of population >75 years, DM prevalence, HT quality, ethnicity and deprivation index and predicted 40% of variation (R(2) = 0.4, P < 0.001).
CONCLUSION: Our findings add prevalence of DM and quality of HT management to the known predictors of variation in RRT, ethnicity and deprivation. They raise the possibility that interventions in primary care might influence later events in specialist care.

Entities:  

Mesh:

Year:  2011        PMID: 21677297     DOI: 10.1093/ndt/gfr347

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Quality of chronic kidney disease management in primary care: a retrospective study.

Authors:  Vincent A Van Gelder; Nynke D Scherpbier-De Haan; Wim J C De Grauw; Gerald M M Vervoort; Chris Van Weel; Marion C J Biermans; Jozé C C Braspenning; Jack F M Wetzels
Journal:  Scand J Prim Health Care       Date:  2016-02-06       Impact factor: 2.581

2.  Informatics as tool for quality improvement: rapid implementation of guidance for the management of chronic kidney disease in England as an exemplar.

Authors:  Simon de Lusignan
Journal:  Healthc Inform Res       Date:  2013-03-31

3.  Predicting the prevalence of chronic kidney disease in the English population: a cross-sectional study.

Authors:  Benjamin Kearns; Hugh Gallagher; Simon de Lusignan
Journal:  BMC Nephrol       Date:  2013-02-25       Impact factor: 2.388

4.  Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results.

Authors:  Simon de Lusignan; Simon de Lusignana; Hugh Gallagher; Simon Jones; Tom Chan; Jeremy van Vlymen; Aumran Tahir; Nicola Thomas; Neerja Jain; Olga Dmitrieva; Imran Rafi; Andrew McGovern; Kevin Harris
Journal:  Kidney Int       Date:  2013-03-27       Impact factor: 10.612

5.  Development of a questionnaire to evaluate practitioners' confidence and knowledge in primary care in managing chronic kidney disease.

Authors:  Mohammad Tahir; Simon Hassan; Simon de Lusignan; Lazza Shaheen; Tom Chan; Olga Dmitrieva
Journal:  BMC Nephrol       Date:  2014-05-07       Impact factor: 2.388

6.  Predictive parameters of arteriovenous fistula maturation in patients with end-stage renal disease.

Authors:  Muhammad A Siddiqui; Suhel Ashraff; Derek Santos; Robert Rush; Thomas Carline; Zahid Raza
Journal:  Kidney Res Clin Pract       Date:  2018-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.